Key words: vasopressin receptors -G-protein * diabetes insipidus * urinary concentration * mutation Nephrogenic diabetes insipidus (NDI) is most often an Xlinked disorder in which urine is not concentrated due to renal resistance to arginine vasopressin. We recently identified four vasopressin type 2 receptor gene mutations in unrelated X-linked NDI families, including R143P, AV278, R202C, and 804insG. All these mutations reduced ligand binding activity to < 10% of the normal without affecting mRNA accumulation. To elucidate whether the receptors are expressed on the cell surface, we analyzed biosynthesis and localization of tagged or untagged receptors stably expressed in Chinese hamster ovary (CHO) cells, using two antibodies directed against distinct termini. Whole-cell and surface labeling studies revealed that the R202C clone had both surface-localized (50-55 kD) and intracellular proteins (40 and 75 kD), similar to the wild-type AVPR2 clone, whereas the R143P and AV278 clones lacked the surface receptors, despite relatively increased intracellular components. The 804insG mutant cell produced no proteins despite an adequate mRNA level. Immunofluorescence staining confirmed that the R202C mutant reaches the cell surface, whereas the R143P and AV278 mutants are retained within the cytoplasmic compartment. Thus, R202C, R143P/ AV278, and 804insG result in three distinct phenotypes, that is, a simple binding impairment at the cell surface, blocked intracellular transport, and ineffective biosynthesis or/and accelerated degradation of the receptor, respectively, and therefore are responsible for NDI. This phenotypic classification will help understanding of molecular pathophysiology of this disorder. (J. Clin. Invest. 1995.
Introduction
Nephrogenic diabetes insipidus (NDI) ' is a rare disorder which is characterized by failure of renal tubules to reabsorb water due to renal tubular resistance to arginine vasopressin (AVP) (1) . Infant males present with clinical manifestations based upon dehydration, unexplained fever, vomiting, and failure to thrive. Persistent dehydration with hypernatremia may lead to consequent mental retardation or even death, if diagnosis and treatment are delayed. Early diagnosis and treatment to ensure an adequate intake of fluid are essential for these patients. While most cases follow an X-linked inheritance mode, autosomal forms of transmission have been described (1) .
In an X-linked form of NDI, previous investigations (2-6) had shown that an arginine vasopressin type 2 receptor (AVPR2) defect could be the molecular basis for lack of concentration of the urine. After cloning of the human AVPR2 cDNA (7, 8) , this hypothesis has been directly tested by polymerase chain reaction (PCR)-based sequencing of the gene from NDI patients. More than 60 AVPR2 gene mutations have been noted in NDI families to date, including missense mutations, small deletion/insertions, tandem duplication, large deletion and nonsense mutations leading to a truncated receptor (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) . Biochemical defects such as impaired binding affinity, capacity, adenylyl cyclase activation, and combination of the three parameters were found in several mutations, e.g., R137H and RI 13W (21-23). The fundamental problem of whether or not the mutant proteins are produced or expressed on the cell surface was addressed in part by Pan et al. (22) , in which a NDI mutation R181C impairs ligand binding but dose not affect surface expression when tagged and expressed transiently in COS cells. However, mechanisms associated with the receptor the 2nd cytoplasmic, 6th transmembrane, 3rd extracellular, and 3rd cytoplasmic domains, respectively ( 15, 24) . The latter three have been detected in other NDI families (16, 18, 19) . We previously expressed these mutations in Chinese hamster ovary (CHO) cell and analyzed their biochemical properties (24, 25) . A R143P clone showed reduced binding capacity (10% of normal) but retained normal binding affinity. Moreover, the cells produced cAMP up to half the normal, suggesting that about 10% of the R143P mutant might have biologically normal functions. On the other hand, CHO cells expressing AV278, R202C, and 804insG had no binding activity, although these cells did produce levels of mRNA similar to the wild-type AVPR2 clone.
Considering that the four mutations greatly reduce or abolish ligand binding activity, it is speculated that the genetic errors could affect efficient receptor translation and subsequent transport to the plasma membrane. To test this possibility, we developed a new receptor-specific antiserum and analyzed localization as well as biosynthesis of the mutant receptors stably expressed in CHO cells. We also used an epitope tagging technique to facilitate surface localization of the receptors. Use of this strategy led to the molecular identification of the receptors with molecular masses of 40, 50-55, and 75 kD. The 50-55-kD protein is presumably localized on the cell surface, whereas the other two masses seem to be the intracellular receptors. We showed here that there is a molecular heterogeneity of the mutants: (a) binding-defective mutant that is normally sorted into the plasma membrane but loses ligand binding activity; (b) transport-defective mutant that is produced but gets trapped in the intracellular organelle; and (c) biosynthesis-defective mutant that is ineffectively translated into the receptor protein. The proposed classification of NDI mutations facilitates understanding of the molecular pathophysiology of NDI and pertinent therapeutic strategies can be developed.
Methods
Stable expression of tagged AVPR2 mutants. Four AVPR2 mutations were identified in unrelated Japanese families with X-linked NDI (15, 24) (Fig. 1) . Cloning of a human AVPR2 cDNA and mutagenesis of the four AVPR2 mutants were described elsewhere (24, 25) . The wildtype and mutant AVPR2 constructs were transfected into Chinese hamster ovary (CHO) cells and the biochemical properties of stable transformants were analyzed (24, 25) (Table I) . To facilitate the surface localization, the epitope sequence GYPYDVPDYA, derived from the influenza hemagglutinin protein (26, 27) , was inserted between the first methionine and leucine residues in the NH2-terminal region of either wild-type and mutant AVPR2s, using polymerase chain reaction (Fig.  2) . The tagged AVPR2 cDNA constructs were subcloned into the eukaryotic expression vector pMT3DSV2 and cotransfected with pSV2neo into dihydrofolate reductase deficient CHO cells by the calcium phosphate method (28) (29) (30) . After selection in a-minimum essential medium without deoxyribonucleosides supplemented with 10% dialyzed fetal bovine serum containing the antibiotic G418 (400 Hg/ml, GIBCO (33) . Briefly, CHO cells expressing wild-type and four mutants of the NH2-terminal tagged AVPR2s were grown on glass coverslips and fixed at room temperature for 20 min in 4% paraformaldehyde in phosphate-buffered saline (PBS). For permeabilization, cells were treated with PBS containing 0.1% Triton X-100. After incubation in a blocking buffer containing 2% fetal calf serum in PBS, specimens were incubated at 37°C for 40 min with the 12CA5 monoclonal antibody diluted by the blocking buffer to 5 Ag/ml. Bound antibody was stained with a secondary antibody of goat antimouse rhodamine conjugate (Protos Immunoresearch, San Francisco, CA) at 1/ 100 dilution. The coverslips were examined and photographed under a fluorescent microscope BH-2 (Olympus Corp., Tokyo, Japan).
Results
Detection of tagged AVPR2 by immunoprecipitation. We first examined biosynthesis and localization of epitope-tagged AVPR2 in CHO cells. Preliminary studies showed that introduction of the 12CA5 epitope into the amino terminal region of AVPR2 did not perturb ligand binding property of the receptor with Kd = 1.3±0.4 nM and Bnax = 2100±340 fmol/mg (mean±+SE, n = 3), compared with that of the native receptor (24, 25) . We cloned several colonies of CHO cells expressing epitope-tagged either wild-type or mutant AVPR2s (R143P, AV278, R202C, and 804insG) and screened receptor mRNA accumulation by Northern blotting. As shown in Fig. 3 , tagged wild-type and mutant receptor expressing cells produced almost equivalent levels of AVPR2 mRNA.
We chose these stable transformants for further analysis regarding the biosynthesis of receptor protein. The biosythetic labeling study on tagged wild-type AVPR2 expressing CHO cells followed by immunoprecipitation with 12CA5 antibody showed that the clone produced two bands at 40 and 75 kD (Fig. 4) . Molecular weight of the 40-kD band was consistent with that calculated for the protein core of the cloned AVPR2 (Mr 40,285) (7), whereas the 75-kD mass presumably reflected the different degrees of glycosylation. These bands were absent in untransfected control CHO cells and were completely absorbed by a competitive assay in the presence of 100 ,IM 12CAS peptide, indicating that the two molecular masses are specifically recognized by the 12CA5 monoclonal antibody. Molecular weights of the receptors were fairly consistent with those of reported by Pan et al. (22) , in which tagged AVPR2s transiently expressed in COS cells were visualized as broad bands right below 43 or 69 kD. Three mutant cell lines (R143P, AV278, and R202C) had the two bands similar to those of the wildtype receptor clone. The relative low density of the receptor proteins for the R202C mutant may be due to a slightly lower level of the receptor mRNA accumulation in the R202C mutant cell (Fig. 3) . On the other hand, the 804insG cell line showed (Fig. 6) clones with monoclonal 12CA5 antibody. The size of the middle band corresponded to that detected by immunoprecipitation of the iodinated cell-surface protein with 12CA5 antibody, suggesting that this band represents surface-localized receptors. However, cell-surface labeling experiments with the polyclonal antiserum revealed no receptor (data not shown). The failure to detect surface proteins probably resulted from the fact that untagged AVPR2 contains only one exofacial tyrosine residue that is a prerequisite for iodination, in contrast to three more tyrosine residues engineered in tagged receptor. One of the AVPR2 mutants, a R202C cell line, showed evidence of species similar to the wild-type AVPR2 expressing cell. On the other hand, R143P and /V278 cell lines displayed more pronounced bands at the 40 and 75 kD but lacked the 50-55-kD protein, and 804insG clone exhibited no detectable bands.
Immunofluorescence localization of tagged AVPR2 in CHO cells. We next tried to examine immunocytochemical localization of the AVPR2 mutants to ask if the mutants are expressed on the cell surface. For this purpose, we chose tagged AVPR2 expressing CHO cells, because the monoclonal antibody provided a more specific staining than did the polyclonal antiserum. We first stained nonpermeabilized cells with the 12CA5 antibody directed against exofacial epitope-tag in the NH2 terminus of the receptor. Untransfected control cells were not detectably stained by the antibody (data not shown). As shown in Fig. 7 A, apparent surface fluorescence was visualized in tagged wildtype and R202C mutant clones. In contrast, R143P and AV278 cell lines lacked the surface signal. Under conditions of permeabilization, both wild-type and mutant (R143P, AV278, and R202C) cells showed considerable fluorescence in the perinuclear region (Fig. 7 B) . Because of the bright staining, we could not determine if the protein accumulated only in the endoplasmic reticulum or was distributed simultaneously in the Golgi complex. However, apparent intracellular staining with the lack of surface signal for the R143P and AV278 mutant cells supported the notion that these mutants are indeed retained within the intracellular compartments, which were compatible with the findings of the immunoprecipitation experiments (Figs. 4-6 ).
Discussion
The present study provides evidence that heterogeneous molecular defects of AVPR2 are associated with NDI. We used an exofacial epitope-tagging technique that facilitates surface localization of the receptors. The specificity of our analysis was verified by findings that two antibodies directed against -the distinct terminal portions of the AVPR2, (i.e., 12CA5 antibody and polyclonal antiserum recognize amino-and carboxyl-termini, respectively), detected the same molecular masses. Using the two antibodies, we identified a molecular mass of the surface-localized receptor which was not found in the Western blotting experiment with epitope tagging AVPR2 (22) . The molecular size of the surface receptor (50-55 kD) is fairly compatible with that predicted from chemical cross-linking studies (60 kD) (34) . However, it should be noted that the 50-55-kD protein was detected in the surface iodination experiments using 12CA5 antibody, whereas the putative surface component was not visualized in the biosynthetic labeling study using the same antibody. On the other hand, the 50-55-kD species were clearly evident when we immunoprecipitated the labeled whole-cell proteins with the polyclonal antiserum. One explanation for this difference is that the surface receptors may be poorly recognized by the 12CA5 antibody. Considering that the epitope is engineered near the putative glycosylation site of the NH2 terminus, it is possible that the bulky complex carbohydrate of the 50-55-kD protein structurally hinders the epitope, thereby preventing the immunorecognition. Nevertheless, this problem was overcome by analyzing both surface-and biosynthetic-labeled proteins and concomitant use of a receptor-specific polyclonal antiserum.
We showed that AVPR2 mutations can be classified into at least three distinct phenotypes. The first type is observed in a R202C mutant which reaches the cell surface but loses binding activity. This characteristic was noted in another mutation of a R181C, similarly creating a new cysteine residue in the third extracellular domain (22) . The results suggest that these mutations do not affect surface expression of the receptor and fail to achieve a proper conformation to access the ligand at the plasma membrane. A possible explanation is that a new extracellular cysteine residue might form de novo disulfide bonds, thereby preventing the protein from folding correctly for ligand binding (35) We propose a new phenotypic classification of AVPR2 mutants. Despite the genetic information available for this disorder, the biological effects have been elucidated in only a limited number of the AVPR2 mutations. Our strategy for a phenotypic classification would be used as a powerful tool to address the fundamental problem of this disease, whether or not the mutant receptors are on the cell surface. The elucidation of the receptor localization will much broaden the knowledge of the structural and function relationship of the receptor. For example, a ligandbinding defective mutant which was formerly determined by a biochemical analysis could be further divided into distinct subtypes of a simple binding-, or intracellular transport-, or biosynthesis-defective mutant. Such information should lead to improve therapy for NDI. A defect due to pure binding problem as found in a R202C mutation could be overcome by correcting the signaling pathway, using a newly designed receptor-agonist.
